HCV RNA Monitoring System

Safeguard your patients. Secure the integrity of your data. Streamline your process and save time.

Much of HCV RNA monitoring in clinical trials is done manually.

That's thousands of manual steps, thousands of minutes wasted, and thousands of possible mistakes.

There is a better way.

Allow us to introduce the only fully automated, validated, 21 CFR Part 11 **HCV RNA Monitoring System** on the market.

This unique tool was developed by the Duke Clinical Research Institute, the world's largest academic research organization, which has renowned expertise in conducting hepatitis C trials.

See the difference:

- The DCRI HCV RNA Monitoring System securely integrates data from multiple sources to accurately make treatment recommendations per protocol specifications.
- Recommendations are sent to a board-certified physician to decide if the patient should continue receiving treatment or if the treatment should be stopped. Signs of drug resistance and/or nonresponse are monitored closely.
- Staff at the study site are notified electronically of pending decisions, which must be acknowledged and confirmed.
- Auditable records of all laboratory values, calculations, recommendations, decisions, notifications, and decision confirmations are kept in the system.

Redefining HCV RNA Monitoring

- Secure and automated transfer of laboratory data to the HCV RNA Monitoring System database reduces the risk of losing critical information and eliminates the need for manual data receipt, manipulation, and entry.

- Rules are programmed according to study design specifications to ensure data accuracy and consistency, reduce errors associated with workflow processes, and deliver prompts at critical time points.

- Seamless communication and confirmation of events, coupled with authenticated, traceable, and verified data and workflow processes, enhance patient safety and data quality.

- Role-based user accounts control access to blinded data and enable monitoring on studies requiring double-blind trial design.

- Simultaneous presentation of current and historical data increases speed of information retrieval.

- Elimination of paper reports, spreadsheets, and faxes to track and manage patient treatment enhances efficiency.

For more information, please contact:

Jenny Brews, MBA
Assistant Director for Business Development
GI and Hepatology Research
Duke Clinical Research Institute
Phone: 919.668.8571
E-mail: jenny.brews@duke.edu

https://dcri.org/our-research/hepatology-gi

Duke Clinical Research Institute
From Thought Leadership to Clinical Practice